3 Branded Generics Company, Specialty Prescription Brand Owner and Active Ingredients Producer Stocks With a Strong Future Roadmap: Lincoln Pharmaceuticals, Ajanta Pharma and Laurus Labs
- October 29, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Lincoln Pharmaceuticals, Ajanta Pharma and Laurus Labs: ROE of 11.6% to 23.3% and FY22 to FY26 revenue CAGR of 8.5% to 12.9%. Prices as of 27 Oct 2026.
Quick Answer
The three branded generics, specialty and API pharma to watch are Lincoln Pharmaceuticals, Ajanta Pharma and Laurus Labs. Their return on equity ranges from 11.6% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 12.9%. Ajanta Pharma leads on both return on equity at 23.3% and revenue growth at 12.9% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.
Branded generics, specialty and API pharma bring together companies with a visible plan for the years ahead. Lincoln Pharmaceuticals, Ajanta Pharma and Laurus Labs cover a branded generics company, a specialty prescription brand owner and an active ingredients producer.
This list covers three branded generics, specialty and API pharma with complete current figures: Lincoln Pharmaceuticals, Ajanta Pharma and Laurus Labs. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Branded Generics, Specialty and API Pharma?
Branded generics, specialty and API pharma are listed pharmaceutical companies that sell branded generics in India and emerging markets, focus on specialty prescription brands and produce active ingredients, formulations and custom synthesis products. Their earnings depend on launches, approvals and export demand.
Branded Generics, Specialty and API Pharma at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Lincoln Pharmaceuticals | 558.1 | 1,067 | 11.1 | 36.0 | 11.6 | 0.01 |
| Ajanta Pharma | 3,459.8 | 41,241 | 36.3 | 36.0 | 23.3 | 0.06 |
| Laurus Labs | 2,181.9 | 111,434 | 102.2 | 36.0 | 16.8 | 0.48 |
On valuation, Lincoln Pharmaceuticals trades at a P/E below the industry P/E, while Ajanta Pharma and Laurus Labs trade above it, which reflects the growth the market already expects. Readers comparing branded generics, specialty and API pharma should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Branded Generics, Specialty and API Pharma Have a Strong Roadmap in India?
Branded generics, specialty and API pharma have a strong roadmap in India because wider access to affordable medicines, steady specialty brand demand and global supply diversification keep widening the market for Indian pharmaceutical firms.
- Branded generics. Trusted brands support repeat demand.
- Specialty brands. Focused therapies build strong shares.
- Ingredient supply. Customers diversify sourcing to India.
Why Lincoln Pharmaceuticals Features Among These Branded Generics, Specialty and API Pharma
Among the branded generics, specialty and API pharma on this list, Lincoln Pharmaceuticals is an Ahmedabad-based maker of branded generics and formulations in India and exports to emerging markets, with products across anti-infectives, respiratory and pain care.
In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%.
Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0.
Roadmap: The company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
What to watch: Track branded product growth, export orders and new launches.
Why Ajanta Pharma Features Among These Branded Generics, Specialty and API Pharma
Among the domestic brands, dermatology and API shares on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.
The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.
Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore.
Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
What to watch: Monitor the pace of new launches in branded markets and the momentum in the United States generics business.
Why Laurus Labs Features Among These Branded Generics, Specialty and API Pharma
Among the three companies on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.
Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%.
In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0.
Roadmap: The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
What to watch: Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.
Lincoln Pharmaceuticals vs Ajanta Pharma vs Laurus Labs on Key Financials
The table below sets the three branded generics, specialty and API pharma side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Lincoln Pharmaceuticals | 482 | 704 | 9.9% | 87.9 | 12.5% |
| Ajanta Pharma | 3,457 | 5,625 | 12.9% | 1,056 | 18.8% |
| Laurus Labs | 4,951 | 6,868 | 8.5% | 890 | 13.0% |
Ajanta Pharma posts the highest return on equity in this group at 23.3%. Laurus Labs has the largest FY26 revenue at Rs 6,868 crore, and Ajanta Pharma shows the fastest revenue growth with a 12.9% compound annual rate. A useful habit with branded generics, specialty and API pharma is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Lincoln Pharmaceuticals | 169 | 202 | 19.0% |
| Ajanta Pharma | 1,329 | 1,697 | 27.7% |
| Laurus Labs | 1,580 | 2,035 | 28.8% |
Key Risks to Check Before Investing in Branded Generics, Specialty and API Pharma
Every theme carries risks that deserve a check before any decision. For these branded generics, specialty and API pharma, the main points are: Long-term domestic brands, dermatology and API shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Pricing pressure. Generic prices can change by market.
- Currency moves. Export earnings move with the rupee.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter branded generics, specialty and API pharma by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Branded Generics, Specialty and API Pharma
Branded generics, specialty and API pharma suit investors who prefer to study business strength before price moves. Lincoln Pharmaceuticals, Ajanta Pharma and Laurus Labs each have a clear plan to grow. Based on the 27 October 2026 close, Lincoln Pharmaceuticals trades at Rs 558.1, Ajanta Pharma at Rs 3,459.8 and Laurus Labs at Rs 2,181.9. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these branded generics, specialty and API pharma to a watchlist.
Download the Univest iOS App or Univest Android App to track branded generics, specialty and API pharma, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are branded generics, specialty and API pharma?
Ans. Branded generics, specialty and API pharma are listed pharmaceutical companies that sell branded generics in India and emerging markets, focus on specialty prescription brands and produce active ingredients, formulations and custom synthesis products. Their earnings depend on launches, approvals and export demand. This list looks at three of them, Lincoln Pharmaceuticals, Ajanta Pharma and Laurus Labs, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.
Which branded generics, specialty and API pharma are covered in this list?
Ans. This list covers Lincoln Pharmaceuticals, Ajanta Pharma and Laurus Labs. Based on the 27 October 2026 close, Lincoln Pharmaceuticals traded at Rs 558.1, Ajanta Pharma at Rs 3,459.8 and Laurus Labs at Rs 2,181.9. Their return on equity ranges from 11.6% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 12.9%.
Why do branded generics, specialty and API pharma have a strong future roadmap in India?
Ans. Branded generics, specialty and API pharma have a strong roadmap in India because wider access to affordable medicines, steady specialty brand demand and global supply diversification keep widening the market for Indian pharmaceutical firms. The main drivers are as follows. Branded generics. Trusted brands support repeat demand. Specialty brands. Focused therapies build strong shares. Ingredient supply. Customers diversify sourcing to India. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Lincoln Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0. Looking ahead, the company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
How has Ajanta Pharma performed financially?
Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
How has Laurus Labs performed financially?
Ans. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
What risks should investors check before buying branded generics, specialty and API pharma?
Ans. Investors should check a few risks before buying branded generics, specialty and API pharma. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of branded generics, specialty and API pharma investment advice?
Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.